

**Prognostically Relevant Periprocedural Myocardial Injury and Infarction Associated with Percutaneous Coronary Interventions:  
A Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI)**

Heerajnarain Bulluck<sup>1\*</sup>, Valeria Paradies<sup>2\*</sup>, Emanuele Barbato<sup>3,4</sup>, Andreas Baumbach<sup>5,6</sup>, Hans Erik Botker<sup>7</sup>, Davide Capodanno<sup>8</sup>, Raffaele De Caterina<sup>9</sup>, Claudio Cavallini<sup>10</sup>, Sean M Davidson<sup>11</sup>, Dmitriy N. Feldman<sup>12</sup>, Péter Ferdinandy<sup>13,14</sup>, Sebastiano Gili<sup>15</sup>, Mariann Gyöngyösi<sup>16</sup>, Vijay Kunadian<sup>17</sup>, Sze-Yuan Ooi<sup>18</sup>, Rosalinda Madonna<sup>9,19</sup>, Michael Marber<sup>20</sup>, Roxana Mehran<sup>21,22</sup>, Gjin Ndrepepa<sup>23</sup>, Cinzia Perrino<sup>3</sup>, Stefanie Schüpke<sup>24</sup>, Johanne Silvain<sup>25</sup>, Joost P.G. Sluijter<sup>26,27</sup>, Giuseppe Tarantini<sup>28</sup>, Gabor G. Toth<sup>29</sup>, Linda W. Van Laake<sup>30</sup>, Clemens von Birgelen<sup>31,32</sup>, Michel Zeitouni<sup>25</sup>, Allan S. Jaffe<sup>33</sup>, Kristian Thygesen<sup>7</sup>, Derek J Hausenloy<sup>11,34-37</sup>

\*Joint first authors

**Affiliations**

<sup>1</sup> Department of Cardiology, Norfolk and Norwich University Hospital, Norwich, UK

<sup>2</sup> Cardiology Department, Maasstad Hospital, Rotterdam, the Netherlands

<sup>3</sup> Department of Advanced Biomedical Sciences, University Federico II of Naples, Italy

<sup>4</sup> Cardiovascular Center Aalst OLV Hospital, Aalst, Belgium.

<sup>5</sup> Centre for Cardiovascular Medicine and Devices, William Harvey Research Institute, Queen Mary University of London, Barts Heart Centre, London

<sup>6</sup> Yale University School of Medicine, New Haven, CT, USA

<sup>7</sup> Department of Cardiology, Aarhus University Hospital, DK-8200 Aarhus N, Denmark

<sup>8</sup> Division of Cardiology, A.O.U. "Policlinico-Vittorio Emanuele", University of Catania, Italy

<sup>9</sup> University of Pisa, and Cardiology Division, Pisa University Hospital

<sup>10</sup> Department of Cardiology, Santa Maria della Misericordia Hospital, Perugia, Italy

<sup>11</sup> The Hatter Cardiovascular Institute, University College London, London, UK

<sup>12</sup> Division of Cardiology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, USA

<sup>13</sup> Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary

<sup>14</sup> Pharmahungary Group, Szeged, Hungary

<sup>15</sup> Centro Cardiologico Monzino, IRCCS, Milan, Italy

<sup>16</sup> Department of Cardiology, Medical University of Vienna, A-1090 Vienna, Austria

<sup>17</sup> Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University and Cardiothoracic Centre, Freeman Hospital, Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne, UK

<sup>18</sup> Eastern Heart Clinic, Prince of Wales Hospital, Sydney, Australia

<sup>19</sup> Department of Internal Medicine, University of Texas Medical School in Houston, Houston, Texas

<sup>20</sup> School of Cardiovascular Medicine and Sciences, British Heart Foundation Centre of Excellence and National Institute for Health Research Biomedical Research Centre, St. Thomas' Hospital Campus, King's College London, London, UK

<sup>21</sup> The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, USA

- <sup>22</sup> Clinical Trials Center, Cardiovascular Research Foundation, New York, USA
- <sup>23</sup> Deutsches Herzzentrum München, Technische Universität, Munich, Germany
- <sup>24</sup> Deutsches Herzzentrum München, and DZHK (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany
- <sup>25</sup> Sorbonne Université, ACTION Study Group, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (AP-HP), INSERM UMRS 1166 Paris, France
- <sup>26</sup> Laboratory of Experimental Cardiology, Department of Cardiology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands
- <sup>27</sup> Regenerative Medicine Center Utrecht, Circulatory Health Laboratory, University Utrecht, University Medical Center Utrecht, Utrecht, The Netherlands
- <sup>28</sup> Interventional Cardiology, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Italy
- <sup>29</sup> University Heart Center Graz, Division of Cardiology, Department of Medicine, Medical University Graz, Austria
- <sup>30</sup> Division Heart and Lungs and Regenerative Medicine Center, University Medical Center Utrecht, Utrecht, The Netherlands
- <sup>31</sup> Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, The Netherlands
- <sup>32</sup> Department of Health Technology and Services Research, Faculty BMS, Technical Medical Centre, University of Twente, Enschede, the Netherlands
- <sup>33</sup> Departments of Cardiology and Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota
- <sup>34</sup> Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore, Singapore
- <sup>35</sup> National Heart Research Institute Singapore, National Heart Centre, Singapore
- <sup>36</sup> Yong Loo Lin School of Medicine, National University Singapore, Singapore
- <sup>37</sup> Cardiovascular Research Center, College of Medical and Health Sciences, Asia University, Taiwan

**Corresponding author:**

Professor Derek Hausenloy  
Cardiovascular & Metabolic Disorders Program,  
Duke-National University of Singapore, 8 College Road,  
Singapore 169857.  
Tel +65 8405 3767  
Email [derek.hausenloy@duke-nus.edu.sg](mailto:derek.hausenloy@duke-nus.edu.sg)

## **DISCLOSURES**

A.B. has received institutional research support from Abbott Vascular and honoraria from Astra Zeneca, Sinomed, Microport, Abbott Vascular, Cardinal Health, KSH. C.vB. indicates that the Research Department of Thoraxcentrum Twente has received institutional research grants from Abbott Vascular, Biotronik, Boston Scientific and Medtronic, not related to the present work. D.C. has received speakers' honoraria or fees from Abbott Vascular, AstraZeneca, Bayer, Boehringer-Ingelheim, Biosensors, and Daiichi Sankyo. R.D.C. has received research funding from Boehringer-Ingelheim, Bayer, BMS/Pfizer, Daiichi-Sankyo and Novartis; and personal fees and honoraria from Boehringer-Ingelheim, Bayer, BMS/Pfizer, Daiichi-Sankyo, Novartis, Amgen, Roche, Sanofi, and Portola. P.F. is an owner of Pharmahungary Group, a group of R&D companies. A.S.J. presently or has in the past consulted for most of the major diagnostic companies. L.V.L. has received research support or honoraria from Abbott, Medtronic, Novartis, Roche, Sopachem, and Vifor. M.M. is named as an inventor on a patent held by King's College London for the detection of cardiac myosin-binding protein C as a biomarker of myocardial injury. R.M. has received research funding from Incyte and Sanofi and honoraria from Actelion. S.S. has received consulting fees from Bayer Vital GmbH, and lecture fees from Daiichi Sankyo and Biopas Laboratoires. G.T. receives consultancy fees from Biotronik, Medtronic and Abbott and unrestricted research support from Medtronic and Abbott. V.K. has received consulting fees/honoraria from Bayer, Amgen, Daiichi Sankyo, Abbot Vascular, Astra Zeneca and major institutional research grant from Astra Zeneca. J. Silvain reports during the past 2 years the following disclosures: Consulting Fees or Lecture Fees or Travel Support from AstraZeneca, Bayer HealthCare SAS, Abbott Medical France SAS, Biotronik, Boehringer Ingelheim France, CSL Behring SA, Gilead Science, Sanofi-Aventis France, Terumo France SAS and Zoll. Stockholder of Pharmaseeds. M.Z. declares research grants from Fédération Française de Cardiologie, Institut Servier, and honorarium from BMS/Pfizer and Bayer. DJH has received consulting fees or honoraria from Faraday Pharmaceuticals Inc., Boehringer Ingelheim and Servier, but these are not related to the present work. All other authors have no relevant disclosures.

## **Abstract**

A substantial number of chronic coronary syndrome (CCS) patients undergoing percutaneous coronary intervention (PCI) experience periprocedural myocardial injury or infarction. Accurate diagnosis of these PCI-related complications is required to guide further management given that their occurrence may be associated with increased risk of major adverse cardiovascular events (MACE). Due to lack of scientific data, the cut-off thresholds of post-PCI cardiac troponin (cTn) elevation used for defining periprocedural myocardial injury and infarction, have been selected based on consensus expert opinions, and their prognostic relevance remain unclear. In this Consensus Document from the ESC Working Group on Cellular Biology of the Heart and EAPCI, we recommend, whenever possible, the measurement of baseline (pre-PCI) cTn and post-PCI cTn values in all CCS patients undergoing PCI. We confirm the prognostic relevance of the post-PCI cTn elevation  $>5 \times 99^{\text{th}}$  percentile URL threshold used to define type 4a MI. In the absence of periprocedural angiographic flow-limiting complications or ECG and imaging evidence of new myocardial ischaemia, we propose the same post-PCI cTn cut-off threshold ( $>5 \times 99^{\text{th}}$  percentile URL) be used to define prognostically relevant 'major' periprocedural myocardial injury. As both type 4a MI and major periprocedural myocardial injury are strong independent predictors of all-cause mortality at one-year post-PCI, they may be used as quality metrics and surrogate endpoints for clinical trials. Further research is needed to evaluate treatment strategies for reducing the risk of major periprocedural myocardial injury, type 4a MI and MACE in CCS patients undergoing PCI.

## 1. Introduction

Percutaneous coronary intervention (PCI) remains the major revascularisation strategy for patients with obstructive coronary artery disease (CAD), with an estimated 5 million procedures performed worldwide each year<sup>1</sup>. In a substantial number of PCI cases for acute coronary syndrome (ACS) and chronic coronary syndrome (CCS)<sup>2</sup>, periprocedural myocardial injury or myocardial infarction (MI) occurs<sup>3</sup>, the actual incidences of which depend on the cardiac biomarker measured and the definitions used. Both these PCI-related complications may be associated with an increased risk of future major adverse cardiovascular events (such as death, reinfarction, and revascularisation)<sup>3,4</sup>. Due to lack of scientific data, the cut-off thresholds of post-PCI elevations of cardiac troponin (cTn) values used for defining periprocedural myocardial injury and MI have been based on expert consensus opinions<sup>5-7</sup>. As such, evidence-based cut-off thresholds of post-PCI cTn elevations for defining prognostically relevant periprocedural myocardial injury and MI need to be established. This is particularly important given the use of periprocedural MI as part of the primary composite endpoint in recent clinical trials of CCS patients undergoing PCI<sup>8-11</sup>. Furthermore, the choice of periprocedural MI definition has been shown to influence the outcomes of recent clinical trials including ISCHEMIA<sup>12,13</sup>, SYNTAXES<sup>14</sup>, and EXCEL<sup>15</sup>.

In this Consensus Document by the European Society of Cardiology (ESC) Working Group on Cellular Biology of the Heart and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), we review the latest scientific data evaluating the prognostic relevance of post-PCI cTn elevations. We have restricted our focus to CCS patients undergoing PCI with normal baseline or elevated but stable baseline (pre-PCI) cTn values, although periprocedural myocardial injury and type 4a MI are of course also relevant to ACS patients undergoing urgent PCI. The aims of our Consensus Document are as follows: (1) establish the cut-off thresholds of post-PCI cTn elevations for defining prognostically relevant periprocedural myocardial injury and type 4a MI; (2) determine the incidences of periprocedural myocardial injury and type 4a MI; (3) identify the patient features, lesion characteristics, and periprocedural factors which independently predict future major adverse cardiac events (MACE); and (4) provide recommendations for the diagnosis of periprocedural myocardial injury or type 4a MI.

## 2. Defining periprocedural myocardial infarction and injury

A number of different diagnostic criteria have been proposed to define periprocedural MI (**Table 1, Suppl. Table 1**). Whereas the Universal Definition of Myocardial Infarction (UDMI) task force has based the definition of type 4a MI on relatively low thresholds of cardiac biomarker elevations together with the presence of new myocardial ischaemia, the Society for Cardiovascular Angiography and Interventions (SCAI)<sup>21</sup> and Academic Research Consortium-2 (ARC-2)<sup>6</sup> have proposed higher thresholds of cardiac biomarker elevation to define periprocedural MI. More centres are changing from conventional cTn to high-sensitivity cTn (hs-cTn) assays, and the latter have been used to define periprocedural MI<sup>6,7</sup>. As expected, the incidence of periprocedural MI in CCS patients varies according to the definition and cardiac biomarker used. For type 4a MI (Third UDMI) the incidence was 7% with hs-cTn<sup>3</sup>, and 10% with cTnT<sup>22</sup>, whereas for the SCAI definition of periprocedural MI the incidence was only 1.5% to 2.9%<sup>3,23</sup>.

In the absence of ECG, angiography or imaging evidence of new myocardial ischaemia required for the Fourth UDMI definition of type 4a MI, periprocedural myocardial injury following PCI, as detected by post-PCI elevation of cTn values, should prompt a search for the underlying aetiology (**Section 4**). As with type 4a MI, there exist a number of different

definitions for periprocedural myocardial injury in CCS patients undergoing PCI (**Table 1, Suppl. Table 1**). The Fourth UDMI<sup>7</sup> has defined periprocedural myocardial injury as any post-PCI elevation of cTn  $>1 \times 99^{\text{th}}$  percentile URL in patients with normal baseline (pre-PCI) values. In contrast, ARC-2 has defined significant periprocedural myocardial injury at a much higher threshold of post-PCI cTn elevation ( $\geq 70 \times 99^{\text{th}}$  percentile URL)<sup>6</sup>. As expected, the incidence of periprocedural myocardial injury varies according to the definition and cardiac biomarker used from as low as 2.9% (according to ARC-2 criteria)<sup>23</sup>, to 20% to 43% with conventional cTnT<sup>24;25</sup> and 14% to 52% with conventional cTnI<sup>26;27</sup>, to as high as 78% to 85% with hs-cTnT<sup>28;29</sup>.

- In summary, there is a lack of consensus for defining periprocedural myocardial infarction and injury, with the SCAI and ARC definitions stipulating much higher thresholds of post-PCI cTn elevation when compared to the Fourth UDMI.

### **3. Detection of periprocedural myocardial injury and type 4a MI associated with PCI**

#### **3.1. Role of cardiac biomarkers**

The most sensitive and specific cardiac biomarkers for detecting periprocedural myocardial injury and type 4a MI are post-PCI elevations of hs-cTnI/T values<sup>30-32</sup>. The diagnostic performances of hs-cTnI/T are significantly better than conventional cTnI/T<sup>30</sup>, and abundant cytosolic proteins such as creatine kinase (CK), CK-MB, Heart-type Fatty Acid Binding Protein, myoglobin and glycogen phosphorylase. Hs-cTnT/I also outperform protein biomarkers produced outside the heart such as copeptin, C-reactive protein, sCD40, ST2 and myeloperoxidase<sup>33</sup>. There are some specific issues to take into consideration with the hs-cTnT/I assays when interpreting baseline (pre-PCI) values. Chronic elevations of hs-cTnT/I values can be present in up to 30% of patients, due to comorbidities and risk factors, such as chronic kidney disease, diabetes, structural heart disease, skeletal muscle disease, malignancies and advanced age<sup>34;35</sup>. Other cardiac-restricted proteins, such as cardiac myosin-binding protein C (cMyC), may challenge hs-cTnT/I<sup>36</sup>, but these assays are not widely available. Although pre-PCI circulating microRNAs have been shown to predict post-PCI outcomes, such as coronary artery restenosis<sup>37;38</sup>, their ability to predict the occurrence of periprocedural myocardial injury and type 4a MI is not known, and they are less sensitive than hs-cTnT/I and cMyC<sup>39</sup>.

- In summary, hs-cTn is the cardiac biomarker of choice for detecting periprocedural myocardial injury and type 4a MI in CCS patients undergoing PCI.

#### **3.2. Role of the ECG**

Compared to a pre-procedural ECG, new ischaemic ECG changes such as new ST-elevation at the J-point or new horizontal or downsloping ST-depression in two contiguous leads or new pathological Q waves are one of the requirements to define type 4a MI according to the Fourth UDMI<sup>7</sup>. It should be noted that isolated post-PCI development of new pathological Q waves meets the type 4a MI criteria even if cTn values are elevated and rising but  $<5 \times 99^{\text{th}}$  percentile URL<sup>7</sup>. The presence of pre-existing left bundle branch block (LBBB) makes the diagnosis of new ischaemic changes challenging. However, in patients with LBBB, ST-elevation  $\geq 1$  mm concordant with the QRS complex in any lead may be an indicator of acute myocardial ischaemia<sup>7</sup>.

- In summary, new ischaemic ST-segment changes and/or pathological Q waves on ECG are one of the key criteria for defining type 4a MI in CCS patients undergoing PCI.

### 3.3. Role of cardiac imaging

Transthoracic echocardiography is the most accessible and available imaging modality for detecting new loss of viable myocardium or new regional wall motion abnormality (RWMA) as one of the diagnostic imaging criteria for defining type 4a MI. However, its comparative lack of sensitivity makes it challenging to detect type 4a MI. Sensitivity may be improved with use of contrast agents that enhance endocardial visualisation<sup>40</sup>, and with advanced echocardiography imaging modalities, such as tissue Doppler imaging or speckle tracking, which may detect more subtle RWMA<sup>41</sup>. Due to limitations in spatial image resolution, it may be challenging to detect type 4a MI using myocardial perfusion scintigraphy (SPECT or PET), unless the area of irreversible myocardial injury is comparatively large. Although contrast-enhanced computed tomography can detect irreversible myocardial injury in ACS patients<sup>42;43</sup>, its role in imaging type 4a MI following PCI in CCS patients has not been tested.

Late gadolinium enhancement cardiovascular magnetic resonance (LGE-CMR) is the gold-standard imaging technique for detection and quantification of irreversible myocardial injury. It has been used to detect type 4a MI in CCS and ACS patients, and has provided unique insights into the underlying pathophysiology. The median mass of new irreversible myocardial injury detected by LGE-CMR ranges from 0.8 g<sup>44</sup> to 5 g<sup>45</sup>, and new LGE occurs in 16%<sup>46</sup> to 63%<sup>47</sup> of CCS patients following PCI, and its presence correlates with post-PCI elevations of CK-MB<sup>48</sup> and cTn<sup>49</sup>. It occurs in two distinct patterns<sup>47-51</sup> - new LGE immediately adjacent to the stent, due to minor incidental side-branch occlusion (SBO), and new LGE distal to the stent due to distal coronary embolisation of atheromatous material. New LGE on CMR is associated with a 3.1-fold increase in MACE at a median follow-up of 2.9 years<sup>45</sup>, although only modest correlations have been shown with type 4a MI (according to Second UDMI)<sup>44</sup>. LGE-CMR imaging may however miss the occurrence of periprocedural myocardial injury detected by minor elevations of post-PCI cTn values due to the latter's higher sensitivity<sup>52</sup>. Although CMR has higher sensitivity for detection of new loss of viable myocardium as part of the diagnostic criteria of type 4a MI, its use is mainly restricted to research studies because of its limited availability.

- In summary, transthoracic echocardiography is the most accessible and available imaging modality for detecting new loss of viable myocardium or RWMA for defining type 4a MI in CCS patients following PCI, although it lacks sensitivity when compared to other cardiac imaging modalities such as CMR.

### 3.4. Role of coronary angiography

One of the key criteria for diagnosing type 4a MI in CCS patients following PCI according to the Fourth UDMI<sup>7</sup> is new myocardial ischaemia as evidenced by coronary angiographic findings consistent with periprocedural flow-limiting complications, such as coronary dissection, occlusion of a major epicardial artery, side branch occlusion/thrombus, disruption of collateral flow, or distal embolisation. ARC-2<sup>6</sup> has provided detailed criteria for defining flow-limiting coronary angiographic complications in PCI patients with suspected periprocedural MI. Interestingly, PCI complications detected on angiography may not always be associated with cardiac biomarker elevations, and minor elevations in cardiac biomarkers may occur due to plaque disruption and local vessel injury without any obvious coronary angiographic complications. Intravascular imaging modalities may be used to complement coronary angiography findings in understanding the pathophysiology of PCI complications.

- In summary, periprocedural flow-limiting complications on coronary angiography are one of the key criteria for diagnosing type 4a MI in CCS patients undergoing PCI.

#### 4. Aetiology of periprocedural myocardial injury and type 4a MI

The aetiology of periprocedural myocardial injury and type 4a MI is multifactorial and may result from PCI-related events or complications, alone or in combination (**Figure 1**). The pathophysiology underlying periprocedural myocardial injury and type 4a MI is inherently very different from type 1 MI. The former is related to the PCI procedure and occurs in the controlled setting of a catheter laboratory, whereas the latter often occurs as an emergency outside the hospital, and is characterised by spontaneous coronary plaque rupture and thrombosis and an associated systemic inflammatory response<sup>7</sup>. SBO is considered to be the most common cause of type 4a MI in CCS patients undergoing PCI<sup>53;54</sup>, but it is likely that its impact on outcome depends on the size of the occluded side-branches. The incidence of SBO may be associated with the choice of stent type, but also with the type of procedure (such as chronic total occlusion [CTO], rotational atherectomy, etc.) and the target segment, with the mid left anterior descending coronary artery having the highest density of side branches<sup>55-57</sup>. Irreversible myocardial injury due to SBO following PCI can be imaged by CMR as new LGE adjacent to the stent (**Section 3.3**)<sup>48-50</sup>. Distal coronary embolisation of intracoronary thrombus and atheromatous material can result in no-reflow/slow-flow during PCI in CCS patients. Embolisation may not be preventable, despite current anticoagulant and antiplatelet adjunctive therapy and use of aspiration or protection devices. Irreversible myocardial injury due to coronary embolisation following PCI can be imaged by CMR as new LGE downstream of the stent (**Section 3.3**)<sup>48-50</sup>. Thrombosis and neuro-hormonal activation may induce coronary vasospasm during PCI in the epicardial arteries distal to the intervention site, and may result in no-reflow/slow-reflow and periprocedural myocardial injury<sup>58</sup>. Moreover, coronary microcirculatory vasospasm may arise as a consequence of potent vasoconstrictors, such as serotonin and endothelin, released from activated platelets and endothelium<sup>59</sup>. A neural mechanism of vasoconstriction may also be involved, as  $\alpha$ -adrenoreceptor blockade has been shown to attenuate coronary vasoconstriction and increase coronary flow reserve during PCI<sup>60</sup>. PCI-related factors, such as pre-dilation, partially occlusive devices (such as catheter extension devices, retrograde CTO procedures, atherectomy devices), which are needed for optimal stent placement, can result in prolonged total vessel occlusion times, and induce periprocedural myocardial injury. Abrupt vessel closure during PCI is usually caused by dissection proximal or distal to the stent or acute stent thrombosis. Other potential rare periprocedural causes of myocardial injury include coronary artery wire perforation, air embolisation and arrhythmias. Even transient occlusions of the coronary artery during balloon angioplasty inflations have been reported to increase cTn values during PCI in CCS patients<sup>61</sup>.

- In summary, the aetiology of periprocedural myocardial injury and type 4a MI is multifactorial, with side branch occlusion and distal embolisation being the major causes.

#### 5. Independent predictors of MACE following PCI

A variety of patient features, lesion characteristics, and periprocedural factors have been shown to be independent predictors of periprocedural myocardial injury, type 4a MI and MACE, in CCS patients undergoing PCI (**Table 2, Suppl. Tables 2a and 2b**). Identification of these factors prior to the PCI procedure, may help to identify patients at higher risk of experiencing these periprocedural complications, and allow the implementation of preventive measures (**Table 3**). Accordingly, these factors should be adjusted for using multivariate logistic regression in studies evaluating the prognostic relevance of post-PCI elevations in cTn. Several studies have shown elevated baseline (pre-PCI) cTn values (present in up to 30% of patients), to be strong independent predictors of MACE in CCS patients undergoing PCI<sup>28;34;35;67</sup>. This likely reflects a higher risk patient population in terms of patient risk factors,



coronary plaque burden, and procedure complexity. Accordingly, studies evaluating whether post-PCI cTn elevation is an independent predictor of MACE should either exclude patients with elevated baseline cTn values or adjust for this factor.

## **6. Prognostic relevance of periprocedural myocardial injury and type 4a MI**

Although studies have demonstrated post-PCI elevations of either CK-MB or cTn to be associated with future risk of MACE, cTn (and hs-cTn) have replaced the use of CK-MB at most centres. A number of clinical studies and meta-analyses, but not all, have reported associations between post-PCI elevation of cTn values and increased risk of MACE (**Suppl. Tables 3a-d**). Although several pooled meta-analyses have reported associations between post-PCI elevations of cTn values and clinical outcomes, they did not adjust for factors that are known to impact on the risk of periprocedural myocardial injury, type 4a MI and MACE<sup>4;89-91</sup> (**Suppl. Table 3d**). A recently published large patient-level pooled analysis demonstrated that post-PCI elevations of both CK-MB and cTn values were independently associated with all-cause mortality at one year with the following combinations of fold elevations being predictive of outcome: CK-MB  $\geq 5$  and cTn  $\geq 35$ , CK-MB  $\geq 10$  and cTn  $< 70$ , and CK-MB  $\geq 5$  and cTn  $\geq 70$ <sup>23</sup> (**Suppl. Table 3d**). However, this study did not evaluate whether post-PCI cTn elevation as a continuous variable was predictive of all-cause mortality at one year<sup>23</sup>. Silvain et al<sup>62</sup> have recently performed a patient-level pooled analysis focused on post-PCI cTn elevations (analysing a different set of studies to that by Garcia-Garcia et al<sup>23</sup>) comprising 9081 CCS patients undergoing PCI (**Suppl. Table 3d**). In this study, care was taken to evaluate the baseline (pre-PCI) cTn value to ensure that the appropriate 99<sup>th</sup> percentile URL for the assay was used, and if it was not, the study was excluded. The incidence of type 4a MI in a subset of 2,316 CCS patients undergoing PCI with normal baseline cTn values was 12.7%, and its occurrence was a strong independent predictor of all-cause mortality at one year (adjusted odds ratio [AdjOR] 3.21, 95% confidence interval [1.42-7.27],  $p=0.005$ ). These findings confirm the prognostic relevance of the  $>5x$  99<sup>th</sup> percentile URL cut-off threshold of post-PCI cTn elevation selected by the Fourth UDMI for defining type 4a MI. The incidence of periprocedural myocardial injury (defined as post-PCI cTn elevation  $>1x$  99<sup>th</sup> percentile URL by the Fourth UDMI) in CCS patients with normal baseline cTn values was 52.8% (79.8% if the analysis was restricted to hs-cTn), but periprocedural myocardial injury was not associated with all-cause mortality at one year (**Suppl. Table 3d**)<sup>62</sup>. These findings suggest that the Fourth UDMI definition of periprocedural myocardial injury might be too sensitive, as it is not an independent predictor of all-cause mortality at one-year. However, the study by Silvain et al<sup>62</sup> did find that post-PCI cTn elevations  $>3x$  99<sup>th</sup> percentile URL independently predicted all-cause mortality at one year in CCS patients undergoing PCI, suggesting that even relatively low post-PCI elevations of cTn are prognostically relevant (**Suppl. Table 3d**). The analysis may have been underpowered to detect the prognostic relevance of even smaller changes in cTn values. Receiver operating characteristic curve analysis, identified a post-PCI cTn cut-off elevation of  $>5x$  99<sup>th</sup> percentile URL to be the optimum threshold for independently predicting all-cause mortality at one year in terms of sensitivity and specificity. Prognostically relevant or 'major' periprocedural myocardial injury (defined in this Consensus Document as a post-PCI cTn elevation of  $>5x$  99<sup>th</sup> percentile URL) occurred in 18.2% of patients with normal baseline cTn values, and was an independent predictor of all-cause mortality at one year (AdjOR 2.29 95% CI [1.32-3.97],  $p=0.004$ ). Importantly, this post-PCI cTn threshold is identical to that used in the Fourth UDMI definition of type 4a MI, simplifying the diagnosis of major periprocedural myocardial injury and type 4a MI. As expected the prognostic implications of type 4a MI are greater than major periprocedural myocardial injury following PCI, with the risk of one-year all-

cause mortality being higher in patients with type 4a MI (AdjOR 3.21) when compared to those patients with major periprocedural myocardial injury (AdjOR 2.29)<sup>62</sup>. These findings confirm that the presence of new ischaemic changes on ECG or angiographic evidence of a flow-limiting complication, as required for type 4a MI, do provide additional prognostic information. In this Consensus Document, we define patients with post-PCI cTn elevations >1x but <5x 99<sup>th</sup> percentile URL as having 'minor' periprocedural myocardial injury.

**Figure 2** provides a summary of the definitions, incidence, and impact on clinical outcomes of periprocedural myocardial injury as defined by the Fourth UDMI, major periprocedural myocardial injury, and type 4a MI in CCS patients undergoing PCI.

## **7. Management of periprocedural myocardial injury and type 4a MI**

Current practice guidelines do not provide specific recommendations for diagnosing and managing periprocedural myocardial injury or type 4a MI in CCS patients undergoing PCI<sup>2,92</sup>. Based on a review of current scientific data, and the results of a recent individual-level pooled-analysis<sup>92</sup>, we propose a diagnostic algorithm for periprocedural myocardial injury and type 4a MI in CCS patients with normal (pre-PCI) baseline cTn values undergoing PCI (**Figure 3**). For CCS patients with baseline (pre-PCI) cTn values which are elevated, stable or falling, the post-PCI cTn must rise by >20%, and the absolute post-PCI value must still be >5x 99<sup>th</sup> percentile URL for both major periprocedural myocardial injury and type 4a MI<sup>7</sup> (**Figure 3**).

### **7.1. Before the PCI procedure**

Whether all CCS patients undergoing PCI should undergo routine baseline (pre-PCI) and post-PCI measurements of cTn has been discussed in past guidelines. The ACC/AHA/SCAI 2005 Guideline Update for PCI<sup>93</sup> had originally made a class IIa recommendation for routine measurement of cardiac biomarker levels (CK-MB and/or cTn) in all patients undergoing PCI, and at 8 to 12 h after the procedure, but these recommendations were not included in the ESC/EACTS 2018 Guidelines on myocardial revascularization<sup>92</sup>. In the Fourth UDMI, it was recommended that baseline (pre-PCI) and post-PCI cTn values should be routinely measured to detect the occurrence of periprocedural myocardial injury<sup>7</sup>. In order to make an accurate diagnosis of either major periprocedural myocardial injury or type 4a MI following PCI, prior knowledge of the baseline (pre-PCI) cTn level is required to correctly interpret post-PCI elevations of cTn values.

In this Consensus Document, we recommend that, whenever possible, baseline (pre-PCI) cTn values should be measured in all CCS patients undergoing PCI. For CCS patients undergoing a planned PCI procedure, the blood sample may be undertaken in the cardiac catheterisation laboratory from the arterial sheath prior to PCI, and for those CCS patients undergoing initial diagnostic coronary angiography, the blood sample may be taken via the arterial sheath from only those patients proceeding to PCI. It is appreciated that in some centres, routine measurement of baseline (pre-PCI) cTn values may not be possible in all CCS patients undergoing PCI. In this case, one may consider measurement of baseline (pre-PCI) cTn values in only those with patient features, lesion characteristics, and periprocedural factors that have been shown to independently predict major periprocedural myocardial injury, type 4a MI, and MACE following PCI (see **Table 2**).

The ESC 2017 focused update on Dual Anti-Platelet Therapy (DAPT) in coronary artery disease recommends clopidogrel (600 mg loading dose, 75 mg daily dose) in addition to aspirin in CCS patients undergoing planned PCI (IA recommendation)<sup>94</sup>. This is supported by recent studies in CCS patients undergoing PCI reporting that pretreatment with the potent platelet P2Y<sub>12</sub> inhibitors ticagrelor (pre-PCI and daily for 30 days)<sup>95</sup> or prasugrel (pre-PCI

only)<sup>96</sup>, did not reduce periprocedural myocardial injury or MI, with ticagrelor being associated with an increased risk of minor bleeding at 30 days, when compared to clopidogrel. For DAPT-naïve CCS patients who require PCI following diagnostic coronary angiography, it is probably advisable to delay PCI by >2 hrs or even to the next day, given that a 600 mg loading dose of clopidogrel acts in approximately 2 hours. However, in those rare instances where ad-hoc PCI is urgently required in DAPT-naïve CCS patients, oral loading with soluble aspirin and ticagrelor or crushed prasugrel may be considered given their faster onset of action (30 mins), with clopidogrel given thereafter (600 mg loading dose, 75 mg daily dose). In cases of urgent complex ad-hoc PCI in DAPT-naïve CCS patients, one may also consider intravenous fast-acting cangrelor to achieve rapid platelet inhibition at time of PCI, based on the results of the CHAMPION PHOENIX trial<sup>79</sup>.

Several other therapeutic strategies have been evaluated for their ability to prevent periprocedural myocardial injury and type 4a MI in CCS patients when given prior to PCI (**Table 3**). Of these, there is substantial evidence to show that high-dose statins (e.g., atorvastatin 80 mg or rosuvastatin 40 mg) administered prior to PCI can reduce the risk of periprocedural myocardial injury, type 4a MI, and MACE in CCS patients<sup>75</sup>. Low-dose treatment with the anti-inflammatory agent, colchicine, has been reported to reduce mainly ischaemia-driven clinical events in patients with recent MI<sup>97</sup> and in CCS patients<sup>98</sup>. However, pre-treatment of CCS with high-dose colchicine prior to PCI failed to reduce the incidence of periprocedural myocardial injury (as defined by the Fourth UDMI), type 4a MI, or SCAI-defined periprocedural MI, when compared to placebo<sup>99</sup>. Whether post-PCI treatment with low-dose colchicine can reduce MACE in CCS patients experiencing type 4a MI post-PCI is not known.

## 7.2. During the PCI procedure

In cases of major intra-procedural vascular complications during PCI (e.g., SBO, dissection, plaque shift, thromboembolism, spasm, or no-reflow/slow reflow), emergent treatment to restore coronary blood flow is a priority. Intravascular imaging with IVUS or optical coherence tomography should be considered to identify and correct mechanical factors that might contribute to coronary dissection or stent thrombosis<sup>92</sup>. Glycoprotein IIb/IIIa inhibitors may be considered in specific 'bail-out' situations including high intraprocedural thrombus burden, slow flow, or no-flow with closure of the stented coronary vessel (ESC Class IIa level C recommendation)<sup>92</sup>. In cases of vasospasm or no-reflow, the use of intracoronary vasodilators, such as calcium channel blockers, nitroglycerin, nitroprusside, or adenosine, may be helpful, but there are no data to recommend one drug over the other. CCS patients with these periprocedural complications will of course be at a greater risk of experiencing periprocedural myocardial injury and type 4a MI, and should have post-PCI cTn values measured (**Figure 3**).

## 7.3. Following the PCI procedure

Recurrent ischaemic symptoms post-PCI should prompt immediate ECG assessment and measurement of post-PCI cTn values (Class IC recommendation)<sup>93</sup>. Patients with ischaemic symptoms and new ST-segment elevation should be transferred to the cardiac catheterisation laboratory without delay. The treatment approach should be individualised according to ECG changes, cTn results, nature and extent of the PCI, technical feasibility, and patient characteristics, when deciding the need for repeat coronary angiography.

In the Fourth UDMI, it has been recommended that post-PCI cTn values should be routinely measured to detect the occurrence of periprocedural myocardial injury<sup>7</sup>. Therefore, in this consensus document, we recommend that, whenever possible, all CCS patients undergoing PCI, should have post-PCI cTn values measured at 3 to 6 h post-PCI, and where

cTn values are rising, further blood sampling may be considered to document the peak cTn value at 12 to 24 h post-procedure (**Figure 3**)<sup>7,100</sup>. This is mandatory in those patients who experience periprocedural complications associated with reduced coronary blood flow, or have ECG changes indicative of new myocardial ischaemia, so that a diagnosis of type 4a MI can be made. For those patients who are kept in overnight for observation by their treating physician due to periprocedural complications, it may be feasible to measure cTn values at 3 to 6 h with repeat testing at 12 to 24 h. However, for those patients with uncomplicated PCI who may be discharged on the same day, the measurement of post-PCI cTn values may only be possible at the 3 to 6 h time-point. It is appreciated that in some centres, routine measurement of post-PCI cTn values may not be possible in all CCS patients undergoing PCI. In this case, one may consider measurement of post-PCI cTn values in only those with patient features, lesion characteristics, and procedural factors which have been shown to be independent predictors of major periprocedural myocardial injury, type 4a MI, and MACE following PCI (see **Table 2**).

CCS patients diagnosed with type 4a MI following PCI, based on post-PCI cTn elevations of >5x 99<sup>th</sup> percentile URL within 48 h, and evidence of new myocardial ischaemia (ECG changes or angiography evidence of a flow-limiting complication) should undergo echocardiography or other cardiac imaging to detect the presence of new loss of viable myocardium or new RWMA, and assess left ventricular ejection fraction. CCS patients diagnosed with type 4a MI are at increased risk of all-cause one-year mortality (AdjOR 3.21)<sup>62</sup>, and pharmacotherapy should be optimised to reduce risk of future MACE, as recommended in current ESC revascularisation and CCS guidelines<sup>2,92</sup>. Whether CCS patients with type 4a MI, who are not already on ACE-inhibitors (for heart failure, hypertension, or diabetes) or beta-blockers (for left ventricular [LV] dysfunction or systolic heart failure), would benefit from the addition of these pharmacotherapies to reduce the risk of future MACE is not known, and needs to be evaluated in future studies.

In the absence of new myocardial ischaemia (new ischaemic changes on ECG or angiographic evidence of a flow-limiting complication), a post-PCI cTn elevation of >5x 99<sup>th</sup> percentile URL within 48 h post-procedure indicates the occurrence of prognostically relevant major periprocedural myocardial injury (**Figure 3**)<sup>62</sup>. In these patients, a type 4a MI should be actively excluded by careful review of the ECG (for new ischaemic changes) and coronary angiogram (for any subtle periprocedural flow-limiting complication), and an echocardiogram or other cardiac imaging should be performed to exclude a RWMA and to assess left ventricular ejection fraction<sup>7</sup>. CCS patients diagnosed with major periprocedural myocardial injury are at increased risk of one-year all-cause mortality (AdjOR 2.29)<sup>62</sup>, and pharmacotherapy should be optimised to reduce risk of future MACE, as recommended in ESC revascularisation and CCS guidelines<sup>2,92</sup>. Whether CCS patients with prognostically relevant major periprocedural myocardial injury, who are not already on ACE-inhibitors (for heart failure, hypertension, or diabetes) or beta-blockers (for LV dysfunction or systolic heart failure), would benefit from the addition of these pharmacotherapies to reduce the risk of future MACE is not known, and needs to be evaluated in further studies.

Patients with no periprocedural myocardial injury (post-PCI cTn elevation  $\leq$ 1x 99<sup>th</sup> percentile URL) or only 'minor' periprocedural myocardial injury (post-PCI cTn elevation >1x 99<sup>th</sup> percentile URL but <5x 99<sup>th</sup> percentile URL) (**Figure 3**) should receive pharmacotherapy, as recommended in current ESC revascularisation and CCS guidelines<sup>2,92</sup>.

## 8. Future research directions

A number of gaps remain in our knowledge with regards to both periprocedural myocardial injury and type 4a MI in patients undergoing PCI, and further research is needed to address this.

- The additional work and costs of routine measurement of baseline (pre-PCI) and post-PCI cTn levels in all CCS patients undergoing PCI is justified because it may provide important registry data and enable future research to confirm the prognostic relevance of cTn levels on clinical outcomes, and inform future recommendations in terms of management strategies and new treatments in CCS patients experiencing major periprocedural myocardial injury and type 4a MI following PCI.
- Further studies are needed to evaluate the prognostic relevance of post-PCI elevations of hs-cTn in CCS patients undergoing PCI, given that the majority of clinical studies have used conventional cTn.
- The optimal time-point(s) for measuring post-PCI cTn values to predict future MACE is not known, and the choice of this timescale will need to recognise that some centres, CCS patients undergoing uncomplicated PCI are discharged on the same day.
- Clinical studies are needed to validate the diagnostic criteria for defining prognostically relevant major periprocedural myocardial injury and type 4a MI in CCS patients with elevated baseline (pre-PCI) cTn values – this is currently defined in the Fourth UDMI as a >20% increase in post-PCI cTn<sup>7</sup>.
- The focus of this Consensus Document has been on the prognostic relevance of periprocedural myocardial injury and type 4a MI in CCS patients undergoing PCI. Further studies are needed to evaluate the prognostic relevance of post-PCI cTn elevations in ACS patients, in whom baseline (pre-PCI) cTn values are elevated and rising.
- Further research is needed to discover novel treatments that can be administered to CCS patients prior to PCI to reduce the risk of periprocedural myocardial injury and type 4a MI. In this regard, the incidence of major periprocedural myocardial injury and type 4a MI may serve as prognostically relevant surrogate clinical endpoints for assessing the efficacy of future cardioprotective therapies.
- Further studies are needed to evaluate new treatments for reducing the future risk of MACE, which can be administered following PCI to patients who experience major periprocedural myocardial injury or type 4a MI. In this regard, whether patients who are not already on ACE-inhibitors (for heart failure, hypertension, or diabetes) or beta-blockers (for LV dysfunction or systolic heart failure), would benefit from the addition of these pharmacotherapies to reduce the risk of future MACE, is not known and remains to be tested.
- Periprocedural MI has been used as a primary composite endpoint in recent clinical trials of CCS patients undergoing PCI<sup>12-15</sup>, and the choice of periprocedural MI definition (protocol-specific vs type 4A MI vs SCAI) has been shown to impact on the outcomes of these trials<sup>12-15;101</sup>. As such, further research is needed to better define periprocedural MI when used as a primary composite endpoint in clinical trials. We would recommend that the type 4a MI definition is used in this situation, given its known prognostic impact on mortality<sup>3;62</sup>. Whether modest isolated post-PCI elevations of cTn >5x 99<sup>th</sup> percentile URL (indicative of periprocedural major myocardial injury), should be used as a primary composite endpoint as well needs to be evaluated in future research studies<sup>101</sup>.
- The digital innovation in healthcare has increased the quantity and quality of patient-generated health data. Machine learning algorithms have been used to enhance risk prediction of post-PCI acute kidney injury<sup>102</sup>, bleeding<sup>103;104</sup> and clinical outcomes<sup>105</sup>,

thereby improving clinical decision making before and during PCI in CCS patients. Whether they can also be used to improve risk prediction of post-PCI complications such as periprocedural myocardial injury and type 4a MI is not known, and warrants further investigation.

## 9. Consensus recommendations

- **Baseline (pre-PCI) cTn values:** Baseline (pre-PCI) cTn values should be measured, whenever possible, in all CCS patients undergoing PCI, as knowledge of this information is essential to correctly interpret post-PCI elevations in cTn values<sup>28;34;35;67</sup>, and to diagnose major periprocedural myocardial injury and type 4a MI following PCI (**Figure 3**).
- **Post-PCI cTn values:** Post-PCI cTn values should be measured, whenever possible, at 3 to 6 h post-procedure, and if the values are rising, further sampling may be considered at 12 to 24 h post-procedure in all CCS patients undergoing PCI. For those with concurrent ECG, imaging or angiographic evidence of new myocardial ischaemia, the diagnosis of type 4a MI may apply (**Figure 3**)<sup>7</sup>. For those without concurrent ECG, imaging or angiographic evidence of new myocardial ischaemia, the diagnosis of major periprocedural myocardial injury may apply (**Figure 3**)<sup>62</sup>.
- **Type 4a MI:** In CCS patients with normal baseline (pre-PCI) cTn values ( $\leq 1 \times 99^{\text{th}}$  percentile URL) or elevated but stable baseline cTn values undergoing PCI who experience a type 4a MI, pharmacotherapy should be optimised to reduce risk of future MACE as recommended in current ESC revascularisation and CCS guidelines<sup>2;92</sup>. Whether CCS patients with type 4a MI, who are not already on ACE-inhibitors (for heart failure, hypertension, or diabetes) or beta-blockers (for LV dysfunction or systolic heart failure), would benefit from the addition of these drugs for reducing the risk of future MACE is not known, and needs to be evaluated in time to come studies. As type 4a MI is a strong independent predictor of all-cause mortality at one-year post-PCI, its incidence may be used as a quality metric and surrogate endpoint for clinical trials<sup>3;62;65</sup>.
- **Major periprocedural myocardial injury:** In CCS patients with normal baseline cTn values ( $\leq 1 \times 99^{\text{th}}$  percentile URL) or elevated but stable baseline cTn values undergoing PCI who experience prognostically relevant major periprocedural myocardial injury, defined as post-PCI cTn elevation  $> 5 \times 99^{\text{th}}$  percentile URL (in the absence of ECG, angiographic and imaging evidence of new myocardial ischaemia) within 48 hrs of PCI<sup>62</sup>, pharmacotherapy should be optimised to reduce risk of future MACE as recommended in current ESC revascularisation and CCS guidelines<sup>2;92</sup>. Whether CCS patients with prognostically relevant major periprocedural myocardial injury, who are not already on ACE-inhibitors (for heart failure, hypertension, or diabetes) or beta-blockers (for LV dysfunction or systolic heart failure), would benefit from the addition of beta-blockers or ACE-inhibitors to reduce the risk of future MACE is not known, and needs to be further evaluated. As major periprocedural myocardial injury is an independent predictor of all-cause mortality at one year<sup>62</sup>, its incidence may be used as a quality metric and surrogate endpoint for clinical trials (**Figure 3**).
- **'Minor' periprocedural myocardial injury:** CCS patients with normal baseline cTn values ( $\leq 1 \times 99^{\text{th}}$  percentile URL) undergoing PCI who experience 'minor' periprocedural

myocardial injury, defined as post-PCI cTn elevation of >1x 99<sup>th</sup> percentile URL but ≤5x 99<sup>th</sup> percentile URL (**Figure 3**)<sup>62</sup>, pharmacotherapy should be optimised to reduce risk of future MACE as recommended in current ESC revascularisation and CCS guidelines<sup>2;92</sup>.

- Future clinical studies and meta-analyses evaluating the prognostic relevance of post-PCI elevations in cTn should only include CCS patients with normal baseline (pre-PCI) cTn values (≤1x 99<sup>th</sup> percentile URL), and should adjust for known patient features, lesion characteristics and periprocedural factors, which have been shown to be independent predictors of periprocedural myocardial injury, type 4a MI, and MACE (Table 2).

## 10. Summary

The prognostic relevance of post-PCI elevations in cardiac biomarkers in CCS patients undergoing PCI has long been debated in the literature, and due to lack of scientific data, the cut-off thresholds of post-PCI cTn elevation used for defining periprocedural myocardial injury and infarction, have been selected based on consensus expert opinions<sup>5-7</sup>. With respect to type 4a MI in CCS patients with normal baseline (pre-PCI) cTn or elevated but stable baseline cTn values, published studies<sup>3;65</sup> and a recent patient-level pooled analysis<sup>62</sup> have validated the post-PCI cut-off threshold of cTn >5x 99<sup>th</sup> percentile URL, and have shown it to be a strong independent predictor of all-cause mortality at one year. The major issue has been with periprocedural myocardial injury, which has been defined by the Fourth UDMI, as any post-PCI elevation in cTn >1x 99<sup>th</sup> percentile URL in CCS patients with normal baseline (pre-PCI) cTn values. This cut-off value for post-PCI cTn elevation might be too low given that up to 80% (using hs-cTn) of patients experience periprocedural myocardial injury according to this definition, and the fact that its occurrence does not independently predict all-cause mortality at one year<sup>62</sup>. However, a post-PCI elevation in cTn of >3x 99<sup>th</sup> percentile URL was found to be independently associated with an increased risk of all-cause mortality at one year, suggesting that even relatively low levels of post-PCI cTn elevation are prognostically relevant. It has been reported that the optimum threshold for independently predicting all-cause mortality at one-year post PCI in CCS patients with normal baseline (pre-PCI) cTn values was >5x 99<sup>th</sup> percentile URL<sup>62</sup>. Therefore, in this Consensus Document, we have defined this cut-off to signify the occurrence of prognostically relevant major periprocedural myocardial injury. Importantly, this cut-off threshold is identical to that used to define type 4a MI, thereby simplifying the diagnoses of major periprocedural myocardial injury and type 4a MI. In this Consensus Document, we present a diagnostic algorithm for minor and major periprocedural myocardial injury and type 4a MI in CCS patients undergoing PCI, based on post-PCI cTn values and ECG/imaging/angiographic evidence of new myocardial ischaemia (**Figure 3**). Further research is needed to evaluate novel treatments for reducing the risk of type 4a MI and major periprocedural myocardial injury in CCS patients undergoing PCI, and further studies are needed to evaluate pharmacotherapies for reducing the risk of future MACE in those CCS patients who experience these PCI-related complications.

## References

1. Faxon DP, Leopold JA, Abbott JD, McElhinney DB, Williams DO. Circulation: Cardiovascular Interventions: The First 10 Years. *Circ Cardiovasc Interv.* 2018;**11**:e006901.
2. Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J.* 2020;**41**:407-477.
3. Zeitouni M, Silvain J, Guedeney P, Kerneis M, Yan Y, Overtchouk P, Barthelemy O, Hauguel-Moreau M, Choussat R, Helft G, Le FC, Collet JP, Montalescot G. Periprocedural myocardial infarction and injury in elective coronary stenting. *Eur Heart J.* 2018;**39**:1100-1109.
4. Feldman DN, Kim L, Rene AG, Minutello RM, Bergman G, Wong SC. Prognostic value of cardiac troponin-I or troponin-T elevation following nonemergent percutaneous coronary intervention: A meta-analysis. *Catheter Cardiovasc Interv.* 2011;**77**:1020-1030.
5. Moussa ID, Klein LW, Shah B, Mehran R, Mack MJ, Brilakis ES, Reilly JP, Zoghbi G, Holper E, Stone GW. Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI). *J Am Coll Cardiol.* 2013;**62**:1563-1570.
6. Garcia-Garcia HM, McFadden EP, Farb A, Mehran R, Stone GW, Spertus J, Onuma Y, Morel MA, van Es GA, Zuckerman B, Fearon WF, Taggart D, Kappetein AP, Krucoff MW, Vranckx P, Windecker S, Cutlip D, Serruys PW. Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. *Eur Heart J.* 2018;**39**:2192-2207.
7. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD. Fourth universal definition of myocardial infarction (2018). *Eur Heart J.* 2019;**40**:237-269.
8. Bonaca MP, Wiviott SD, Morrow DA, Steg PG, Hamm C, Bhatt DL, Storey RF, Cohen M, Kuder J, Im K, Magnani G, Budaj A, Nicolau JC, Parkhomenko A, Lopez-Sendon J, Dellborg M, Diaz R, Van de Werf F, Corbalan R, Goudev A, Jensen EC, Johanson P, Braunwald E, Sabatine MS. Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54. *J Am Heart Assoc.* 2018;**7**:e009260.
9. Olivier CB, Mulder H, Hiatt WR, Jones WS, Fowkes FGR, Rockhold FW, Berger JS, Baumgartner I, Held P, Katona BG, Norgren L, Blomster J, Patel MR, Mahaffey KW. Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial. *JAMA Cardiol.* 2019;**4**:7-15.
10. Stone GW, Kappetein AP, Sabik JF, Pocock SJ, Morice MC, Puskas J, Kandzari DE, Karpaliotis D, Brown WM, III, Lembo NJ, Banning A, Merkely B, Horkay F, Boonstra PW, van Boven AJ, Ungi I, Bogats G, Mansour S, Noiseux N, Sabate M, Pomar J, Hickey M, Gershlick A, Buszman PE, Bochenek A, Schampaert E, Page P, Modolo R, Gregson J, Simonton CA, Mehran R, Kosmidou I, Genereux P, Crowley A, Dressler O,



Serruys PW. Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease. *N Engl J Med*. 2019;**381**:1820-1830.

11. Holm NR, Makikallio T, Lindsay MM, Spence MS, Erglis A, Menown IBA, Trovik T, Kellerth T, Kalinauskas G, Mogensen LJH, Nielsen PH, Niemela M, Lassen JF, Oldroyd K, Berg G, Stradins P, Walsh SJ, Graham ANJ, Endresen PC, Frobert O, Trivedi U, Anttila V, Hildick-Smith D, Thuesen L, Christiansen EH. Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5-year outcomes from the randomised, non-inferiority NOBLE trial. *Lancet*. 2020;**395**:191-199.
12. Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O'Brien SM, Boden WE, Chaitman BR, Senior R, Lopez-Sendon J, Alexander KP, Lopes RD, Shaw LJ, Berger JS, Newman JD, Sidhu MS, Goodman SG, Ruzylo W, Gosselin G, Maggioni AP, White HD, Bhargava B, Min JK, Mancini GBJ, Berman DS, Picard MH, Kwong RY, Ali ZA, Mark DB, Spertus JA, Krishnan MN, Elghamaz A, Moorthy N, Hueb WA, Demkow M, Mavromatis K, Bockeria O, Peteiro J, Miller TD, Szwed H, Doerr R, Keltai M, Selvanayagam JB, Steg PG, Held C, Kohsaka S, Mavromichalis S, Kirby R, Jeffries NO, Harrell FE, Jr., Rockhold FW, Broderick S, Ferguson TB, Jr., Williams DO, Harrington RA, Stone GW, Rosenberg Y. Initial Invasive or Conservative Strategy for Stable Coronary Disease. *N Engl J Med*. 2020;**382**:1395-1407.
13. Chaitman BR, Alexander KP, Cyr DD, Berger JS, Reynolds HR, Bangalore S, Boden WE, Lopes RD, Demkow M, Piero PG, Riezebos RK, McFalls EO, Banerjee S, Bagai A, Gosselin G, O'Brien SM, Rockhold FW, Waters DD, Thygesen KA, Stone GW, White HD, Maron DJ, Hochman JS. Myocardial Infarction in the ISCHEMIA Trial: Impact of Different Definitions on Incidence, Prognosis, and Treatment Comparisons. *Circulation*. 2021;**143**:790-804.
14. Hara H, Serruys PW, Takahashi K, Kawashima H, Ono M, Gao C, Wang R, Mohr FW, Holmes DR, Davierwala PM, Head SJ, Thuijs DJFM, Milojevic M, Kappetein AP, Garg S, Onuma Y, Mack MJ. Impact of Peri-Procedural Myocardial Infarction on Outcomes After Revascularization. *J Am Coll Cardiol*. 2020;**76**:1622-1639.
15. Gregson J, Stone GW, Ben-Yehuda O, Redfors B, Kandzari DE, Morice MC, Leon MB, Kosmidou I, Lembo NJ, Brown WM, III, Karpaliotis D, Banning AP, Pomar J, Sabate M, Simonton CA, Dressler O, Kappetein AP, Sabik JF, III, Serruys PW, Pocock SJ. Implications of Alternative Definitions of Peri-Procedural Myocardial Infarction After Coronary Revascularization. *J Am Coll Cardiol*. 2020;**76**:1609-1621.
16. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. *Eur Heart J*. 2000;**21**:1502-1513.
17. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. *Eur Heart J*. 2007;**28**:2525-2538.
18. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW. Clinical end points in coronary stent trials: a case for standardized definitions. *Circulation*. 2007;**115**:2344-2351.
19. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Thygesen K, Alpert JS, White HD, Jaffe AS, Katus HA, Apple FS, Lindahl B, Morrow DA, Chaitman BA, Clemmensen PM, Johanson P, Hod H, Underwood R, Bax JJ, Bonow RO, Pinto

- F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvani M, Hamm CW, Uretsky BF, Steg PG, Wijns W, Bassand JP, Menasche P, Ravkilde J, Ohman EM, Antman EM, Wallentin LC, Armstrong PW, Simoons ML, Januzzi JL, Nieminen MS, Gheorghiu M, Filippatos G, Luepker RV, Fortmann SP, Rosamond WD, Levy D, Wood D, Smith SC, Hu D, Lopez-Sendon JL, Robertson RM, Weaver D, Tendera M, Bove AA, Parkhomenko AN, Vasilieva EJ, Mendis S. Third universal definition of myocardial infarction. *Eur Heart J*. 2012;**33**:2551-2567.
20. Moussa ID, Klein LW, Shah B, Mehran R, Mack MJ, Brilakis ES, Reilly JP, Zoghbi G, Holper E, Stone GW. Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI). *Catheter Cardiovasc Interv*. 2014;**83**:27-36.
  21. Novack V, Pencina M, Cohen DJ, Kleiman NS, Yen CH, Saucedo JF, Berger PB, Cutlip DE. Troponin criteria for myocardial infarction after percutaneous coronary intervention. *Arch Intern Med*. 2012;**172**:502-508.
  22. Yang X, Tamez H, Lai C, Ho K, Cutlip D. Type 4a myocardial infarction: Incidence, risk factors, and long-term outcomes. *Catheter Cardiovasc Interv*. 2017;**89**:849-856.
  23. Garcia-Garcia HM, McFadden EP, von BC, Rademaker-Havinga T, Spitzer E, Kleiman NS, Cohen DJ, Kennedy KF, Camenzind E, Mauri L, Steg PG, Wijns W, Silber S, van Es GA, Serruys PW, Windecker S, Cutlip D, Vranckx P. Impact of Periprocedural Myocardial Biomarker Elevation on Mortality Following Elective Percutaneous Coronary Intervention. *JACC Cardiovasc Interv*. 2019;**12**:1954-1962.
  24. Prasad A, Singh M, Lerman A, Lennon RJ, Holmes DR, Jr., Rihal CS. Isolated elevation in troponin T after percutaneous coronary intervention is associated with higher long-term mortality. *J Am Coll Cardiol*. 2006;**48**:1765-1770.
  25. Herrmann J, Lennon RJ, Jaffe AS, Holmes DR, Jr., Rihal CS, Prasad A. Defining the optimal cardiac troponin T threshold for predicting death caused by periprocedural myocardial infarction after percutaneous coronary intervention. *Circ Cardiovasc Interv*. 2014;**7**:533-542.
  26. Loeb HS, Liu JC. Frequency, risk factors, and effect on long-term survival of increased troponin I following uncomplicated elective percutaneous coronary intervention. *Clin Cardiol*. 2010;**33**:E40-E44.
  27. Feldman DN, Minutello RM, Bergman G, Moussa I, Wong SC. Relation of troponin I levels following nonemergent percutaneous coronary intervention to short- and long-term outcomes. *Am J Cardiol*. 2009;**104**:1210-1215.
  28. Ndrepepa G, Colleran R, Braun S, Cassese S, Hieber J, Fusaro M, Kufner S, Ott I, Byrne RA, Husser O, Hengstenberg C, Laugwitz KL, Schunkert H, Kastrati A. High-Sensitivity Troponin T and Mortality After Elective Percutaneous Coronary Intervention. *J Am Coll Cardiol*. 2016;**68**:2259-2268.
  29. Cottens D, Maeremans J, McCutcheon K, Lamers S, Roux L, Duponselle J, Bennett J, Dens J. Prognostic value of the high-sensitivity troponin T assay after percutaneous intervention of chronic total occlusions. *J Cardiovasc Med (Hagerstown)*. 2018;**19**:366-372.

30. Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C, Hartwiger S, Biedert S, Schaub N, Buerge C, Potocki M, Noveanu M, Breidthardt T, Twerenbold R, Winkler K, Bingisser R, Mueller C. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. *N Engl J Med.* 2009;**361**:858-867.
31. Januzzi JL, Jr., Mahler SA, Christenson RH, Rymer J, Newby LK, Body R, Morrow DA, Jaffe AS. Recommendations for Institutions Transitioning to High-Sensitivity Troponin Testing: JACC Scientific Expert Panel. *J Am Coll Cardiol.* 2019;**73**:1059-1077.
32. Jaffe, A., Giannitsis, E., Mueller, C., Cullen L, Hammarsten O, Moeckel M, Krychtiuk KA, Huber K, Mills NL, and Thygesen, K. A Fond Farewell to CK-MB: Current opinion from the ESC Study Group on Cardiac Biomarkers of the Association for Acute CardioVascular Care. *Eur Heart J.* 2021; Jan 22;ehaa1079. doi: 10.1093/eurheartj/ehaa1079. Online ahead of print.
33. Lipinski MJ, Baker NC, Escarcega RO, Torguson R, Chen F, Aldous SJ, Christ M, Collinson PO, Goodacre SW, Mair J, Inoue K, Lotze U, Sebbane M, Cristol JP, Freund Y, Chenevier-Gobeaux C, Meune C, Eggers KM, Pracon R, Schreiber DH, Wu AH, Ordonez-Llanos J, Jaffe AS, Twerenbold R, Mueller C, Waksman R. Comparison of conventional and high-sensitivity troponin in patients with chest pain: a collaborative meta-analysis. *Am Heart J.* 2015;**169**:6-16.
34. Miller WL, Garratt KN, Burritt MF, Lennon RJ, Reeder GS, Jaffe AS. Baseline troponin level: key to understanding the importance of post-PCI troponin elevations. *Eur Heart J.* 2006;**27**:1061-1069.
35. Prasad A, Rihal CS, Lennon RJ, Singh M, Jaffe AS, Holmes DR, Jr. Significance of periprocedural myonecrosis on outcomes after percutaneous coronary intervention: an analysis of preintervention and postintervention troponin T levels in 5487 patients. *Circ Cardiovasc Interv.* 2008;**1**:10-19.
36. Kaier TE, Twerenbold R, Puelacher C, Marjot J, Imambaccus N, Boeddinghaus J, Nestelberger T, Badertscher P, Sabti Z, Gimenez MR, Wildi K, Hillinger P, Grimm K, Loeffel S, Shrestha S, Widmer DF, Cupa J, Kozhuharov N, Miro O, Martin-Sanchez FJ, Morawiec B, Rentsch K, Lohrmann J, Kloos W, Osswald S, Reichlin T, Weber E, Marber M, Mueller C. Direct Comparison of Cardiac Myosin-Binding Protein C With Cardiac Troponins for the Early Diagnosis of Acute Myocardial Infarction. *Circulation.* 2017;**136**:1495-1508.
37. Dai R, Liu Y, Zhou Y, Xiong X, Zhou W, Li W, Zhou W, Chen M. Potential of circulating pro-angiogenic microRNA expressions as biomarkers for rapid angiographic stenotic progression and restenosis risks in coronary artery disease patients underwent percutaneous coronary intervention. *J Clin Lab Anal.* 2020;**34**:e23013.
38. Guan JJ, Zhang Y, Liu YJ. [Effects of miRNA-1,miRNA-21 in plasma on in-stent restenosis in patients with coronary heart disease and diabetes mellitus after percutaneous coronary intervention]. *Zhongguo Ying Yong Sheng Li Xue Za Zhi.* 2018;**34**:304-308.
39. Schulte C, Barwari T, Joshi A, Theofilatos K, Zampetaki A, Barallobre-Barreiro J, Singh B, Sorensen NA, Neumann JT, Zeller T, Westermann D, Blankenberg S, Marber M, Liebetau C, Mayr M. Comparative Analysis of Circulating Noncoding RNAs Versus Protein Biomarkers in the Detection of Myocardial Injury. *Circ Res.* 2019;**125**:328-340.

40. Senior R, Becher H, Monaghan M, Agati L, Zamorano J, Vanoverschelde JL, Nihoyannopoulos P, Edvardsen T, Lancellotti P. Clinical practice of contrast echocardiography: recommendation by the European Association of Cardiovascular Imaging (EACVI) 2017. *Eur Heart J Cardiovasc Imaging*. 2017;**18**:1205-1205af.
41. Flachskampf FA, Schmid M, Rost C, Achenbach S, DeMaria AN, Daniel WG. Cardiac imaging after myocardial infarction. *Eur Heart J*. 2011;**32**:272-283.
42. Gerber BL, Belge B, Legros GJ, Lim P, Poncelet A, Pasquet A, Gisellu G, Coche E, Vanoverschelde JL. Characterization of acute and chronic myocardial infarcts by multidetector computed tomography: comparison with contrast-enhanced magnetic resonance. *Circulation*. 2006;**113**:823-833.
43. Watabe H, Sato A, Nishina H, Hoshi T, Sugano A, Kakefuda Y, Takaiwa Y, Aihara H, Fumikura Y, Noguchi Y, Aonuma K. Enhancement patterns detected by multidetector computed tomography are associated with microvascular obstruction and left ventricular remodelling in patients with acute myocardial infarction. *Eur Heart J*. 2016;**37**:684-692.
44. Locca D, Bucciarelli-Ducci C, Ferrante G, La MA, Keenan NG, Grasso A, Barlis P, Del FF, Prasad SK, Kaski JC, Pennell DJ, Di MC. New universal definition of myocardial infarction applicable after complex percutaneous coronary interventions? *JACC Cardiovasc Interv*. 2010;**3**:950-958.
45. Rahimi K, Banning AP, Cheng AS, Pegg TJ, Karamitsos TD, Channon KM, Darby S, Taggart DP, Neubauer S, Selvanayagam JB. Prognostic value of coronary revascularisation-related myocardial injury: a cardiac magnetic resonance imaging study. *Heart*. 2009;**95**:1937-1943.
46. van Gaal WJ, Arnold JR, Testa L, Karamitsos T, Lim CC, Ponnuthurai FA, Petersen S, Francis JM, Selvanayagam J, Sayeed R, West N, Westaby S, Neubauer S, Banning AP. Myocardial injury following coronary artery surgery versus angioplasty (MICASA): a randomised trial using biochemical markers and cardiac magnetic resonance imaging. *EuroIntervention*. 2011;**6**:703-710.
47. Selvanayagam JB, Cheng AS, Jerosch-Herold M, Rahimi K, Porto I, van GW, Channon KM, Neubauer S, Banning AP. Effect of distal embolization on myocardial perfusion reserve after percutaneous coronary intervention: a quantitative magnetic resonance perfusion study. *Circulation*. 2007;**116**:1458-1464.
48. Ricciardi MJ, Wu E, Davidson CJ, Choi KM, Klocke FJ, Bonow RO, Judd RM, Kim RJ. Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. *Circulation*. 2001;**103**:2780-2783.
49. Selvanayagam JB, Porto I, Channon K, Petersen SE, Francis JM, Neubauer S, Banning AP. Troponin elevation after percutaneous coronary intervention directly represents the extent of irreversible myocardial injury: insights from cardiovascular magnetic resonance imaging. *Circulation*. 2005;**111**:1027-1032.
50. Choi CJ, Haji-Momenian S, Dimaria JM, Epstein FH, Bove CM, Rogers WJ, Kramer CM. Infarct involution and improved function during healing of acute myocardial infarction: the role of microvascular obstruction. *J Cardiovasc Magn Reson*. 2004;**6**:917-925.

51. Porto I, Selvanayagam JB, van Gaal WJ, Prati F, Cheng A, Channon K, Neubauer S, Banning AP. Plaque volume and occurrence and location of periprocedural myocardial necrosis after percutaneous coronary intervention: insights from delayed-enhancement magnetic resonance imaging, thrombolysis in myocardial infarction myocardial perfusion grade analysis, and intravascular ultrasound. *Circulation*. 2006;**114**:662-669.
52. Marjot J, Kaier TE, Martin ED, Reji SS, Copeland O, Iqbal M, Goodson B, Hamren S, Harding SE, Marber MS. Quantifying the Release of Biomarkers of Myocardial Necrosis from Cardiac Myocytes and Intact Myocardium. *Clin Chem*. 2017;**63**:990-996.
53. Lansky AJ, Stone GW. Periprocedural myocardial infarction: prevalence, prognosis, and prevention. *Circ Cardiovasc Interv*. 2010;**3**:602-610.
54. Babu GG, Walker JM, Yellon DM, Hausenloy DJ. Peri-procedural myocardial injury during percutaneous coronary intervention: an important target for cardioprotection. *Eur Heart J*. 2011;**32**:23-31.
55. Muramatsu T, Onuma Y, Garcia-Garcia HM, Farooq V, Bourantas CV, Morel MA, Li X, Veldhof S, Bartorelli A, Whitbourn R, Abizaid A, Serruys PW. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials. *JACC Cardiovasc Interv*. 2013;**6**:247-257.
56. Ishibashi Y, Muramatsu T, Nakatani S, Sotomi Y, Suwannasom P, Grundeken MJ, Cho YK, Garcia-Garcia HM, van Boven AJ, Piek JJ, Sabate M, Helqvist S, Baumbach A, McClean D, de Sousa AM, Wasungu L, Miquel-Hebert K, Dudek D, Chevalier B, Onuma Y, Serruys PW. Incidence and Potential Mechanism(s) of Post-Procedural Rise of Cardiac Biomarker in Patients With Coronary Artery Narrowing After Implantation of an Everolimus-Eluting Bioresorbable Vascular Scaffold or Everolimus-Eluting Metallic Stent. *JACC Cardiovasc Interv*. 2015;**8**:1053-1063.
57. Lansky AJ, Yaqub M, Hermiller JB, Smith RS, Farhat N, Caputo R, Williams JE, Sanz M, Koo K, Sood P, Sudhir K, Stone GW. Side branch occlusion with everolimus-eluting and paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial. *EuroIntervention*. 2010;**6 Suppl J**:J44-J52.
58. Fischell TA, Derby G, Tse TM, Stadius ML. Coronary artery vasoconstriction routinely occurs after percutaneous transluminal coronary angioplasty. A quantitative arteriographic analysis. *Circulation*. 1988;**78**:1323-1334.
59. Salloum J, Tharpe C, Vaughan D, Zhao DX. Release and elimination of soluble vasoactive factors during percutaneous coronary intervention of saphenous vein grafts: analysis using the PercuSurge GuardWire distal protection device. *J Invasive Cardiol*. 2005;**17**:575-579.
60. Gregorini L, Marco J, Kozakova M, Palombo C, Anguissola GB, Marco I, Bernies M, Cassagneau B, Distante A, Bossi IM, Fajadet J, Heusch G. Alpha-adrenergic blockade improves recovery of myocardial perfusion and function after coronary stenting in patients with acute myocardial infarction. *Circulation*. 1999;**99**:482-490.
61. Arnadottir A, Pedersen S, Hasselbalch RB, Goetze JP, Friis-Hansen LJ, Bloch-Munster AM, Jensen JS, Bundgaard H, Iversen K. Temporal Release of High-

Sensitivity Cardiac Troponin T and I and Copeptin After Brief Induced Coronary Artery Balloon Occlusion in Humans. *Circulation*. 2020.

62. Silvain J, Zeitouni M, Paradies V, Zheng HL, Ndrepepa G, Cavallini C, Feldman DN, Sharma SK, Mehilli J, Gili S, Barbato E, Tarantini G, Ooi SY, von BC, Jaffe AS, Thygesen K, Montalescot G, Bulluck H, Hausenloy DJ. Cardiac procedural myocardial injury, infarction, and mortality in patients undergoing elective percutaneous coronary intervention: a pooled analysis of patient-level data. *Eur Heart J*. 2021;**42**:323-334.
63. Auguadro C, Scalise F, Manfredi M, Casali V, Novelli E, Specchia G. The prognostic role of troponin I elevation after elective percutaneous coronary intervention. *J Cardiovasc Med (Hagerstown)*. 2015;**16**:149-155.
64. Koskinas KC, Ndrepepa G, Raber L, Karagiannis A, Kufner S, Zanchin T, Hieber J, Hunziker L, Mayer K, Byrne RA, Heg D, Windecker S, Kastrati A. Prognostic Impact of Periprocedural Myocardial Infarction in Patients Undergoing Elective Percutaneous Coronary Interventions. *Circ Cardiovasc Interv*. 2018;**11**:e006752.
65. Liou K, Jepson N, Kellar P, Ng B, Isbister J, Giles R, Friedman D, Allan R, Lau A, Pitney M, Ooi SY. Prognostic Significance of Peri-procedural Myocardial Infarction in the Era of High Sensitivity Troponin: A Validation of the Joint ACCF/AHA/ESC/WHF Universal Definition of Type 4a Myocardial Infarction with High Sensitivity Troponin T. *Heart Lung Circ*. 2015;**24**:673-681.
66. Chen ZW, Yang HB, Chen YH, Ma JY, Qian JY, Ge JB. Impact of multi-vessel therapy to the risk of periprocedural myocardial injury after elective coronary intervention: exploratory study. *BMC Cardiovasc Disord*. 2017;**17**:69.
67. Jeremias A, Kleiman NS, Nassif D, Hsieh WH, Pencina M, Maresh K, Parikh M, Cutlip DE, Waksman R, Goldberg S, Berger PB, Cohen DJ. Prevalence and prognostic significance of preprocedural cardiac troponin elevation among patients with stable coronary artery disease undergoing percutaneous coronary intervention: results from the evaluation of drug eluting stents and ischemic events registry. *Circulation*. 2008;**118**:632-638.
68. Di SL, Borgia F, Maeremans J, Pyxaras SA, De BB, Wijns W, Heyndrickx GR, Dens J, Di MC, Barbato E. Periprocedural Myocardial Injury and Long-Term Clinical Outcome in Patients Undergoing Percutaneous Coronary Interventions of Coronary Chronic Total Occlusion. *J Invasive Cardiol*. 2016;**28**:410-414.
69. Patti G, Chello M, Pasceri V, Colonna D, Nusca A, Miglionico M, D'Ambrosio A, Covino E, Di SG. Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. *J Am Coll Cardiol*. 2006;**48**:1560-1566.
70. Ye H, He F, Fei X, Lou Y, Wang S, Yang R, Hu Y, Chen X. High-dose atorvastatin reloading before percutaneous coronary intervention increased circulating endothelial progenitor cells and reduced inflammatory cytokine expression during the perioperative period. *J Cardiovasc Pharmacol Ther*. 2014;**19**:290-295.
71. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di SG. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results

from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. *Circulation*. 2004;**110**:674-678.

72. Mulukutla SR, Marroquin OC, Smith C, Varghese R, Anderson WD, Lee JS, Cohen HA, Counihan PJ, Lee AB, Gulati V, McNamara D. Effect of statin therapy prior to elective percutaneous coronary intervention on frequency of periprocedural myocardial injury. *Am J Cardiol*. 2004;**94**:1363-1366.
73. Briguori C, Visconti G, Focaccio A, Golia B, Chieffo A, Castelli A, Mussardo M, Montorfano M, Ricciardelli B, Colombo A. Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. *J Am Coll Cardiol*. 2009;**54**:2157-2163.
74. Sardella G, Lucisano L, Mancone M, Conti G, Calcagno S, Stio RE, Pennacchi M, Biondi-Zoccai G, Canali E, Fedele F. Comparison of high reloading ROSuvastatin and Atorvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of Myocardial periprocedural necrosis. The ROMA II trial. *Int J Cardiol*. 2013;**168**:3715-3720.
75. Pan Y, Tan Y, Li B, Li X. Efficacy of high-dose rosuvastatin preloading in patients undergoing percutaneous coronary intervention: a meta-analysis of fourteen randomized controlled trials. *Lipids Health Dis*. 2015;**14**:97.
76. Veselka J, Hajek P, Tomasov P, Tesar D, Bruhova H, Matejovic M, Branny M, Studencan M, Zemanek D. Effect of rosuvastatin therapy on troponin I release following percutaneous coronary intervention in nonemergency patients (from the TIP 3 study). *Am J Cardiol*. 2014;**113**:446-451.
77. Zemanek D, Branny M, Martinkovicova L, Hajek P, Maly M, Tesar D, Tomasov P, Veselka J. Effect of seven-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following percutaneous coronary intervention in patients receiving long-term statin therapy. A randomized study. *Int J Cardiol*. 2013;**168**:2494-2497.
78. Madonna R, Renna FV, Lanuti P, Perfetti M, Marchisio M, Briguori C, Condorelli G, Manzoli L, De CR. The acute impact of high-dose lipid-lowering treatment on endothelial progenitor cells in patients with coronary artery disease-The REMEDY-EPC early substudy. *PLoS One*. 2017;**12**:e0172800.
79. Cavender MA, Bhatt DL, Stone GW, White HD, Steg PG, Gibson CM, Hamm CW, Price MJ, Leonardi S, Prats J, Deliargyris EN, Mahaffey KW, Harrington RA. Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). *Circulation*. 2016;**134**:723-733.
80. Hoole S, Heck PM, Sharples L, Khan SN, Duehmke R, Densem CG, Clarke SC, Shapiro LM, Schofield PM, O'Sullivan M, Dutka DP. Cardiac Remote Ischemic Preconditioning in Coronary Stenting (CRISP Stent) Study: a prospective, randomized control trial. *Circulation*. 2009;**119**:820-827.
81. Luo SJ, Zhou YJ, Shi DM, Ge HL, Wang JL, Liu RF. Remote ischemic preconditioning reduces myocardial injury in patients undergoing coronary stent implantation. *Can J Cardiol*. 2013;**29**:1084-1089.

82. Pei H, Wu Y, Wei Y, Yang Y, Teng S, Zhang H. Remote ischemic preconditioning reduces perioperative cardiac and renal events in patients undergoing elective coronary intervention: a meta-analysis of 11 randomized trials. *PLoS One*. 2014;**9**:e115500.
83. Zografos TA, Katritsis GD, Tsiafoutis I, Bourboulis N, Katsivas A, Katritsis DG. Effect of one-cycle remote ischemic preconditioning to reduce myocardial injury during percutaneous coronary intervention. *Am J Cardiol*. 2014;**113**:2013-2017.
84. Davies WR, Brown AJ, Watson W, McCormick LM, West NE, Dutka DP, Hoole SP. Remote Ischemic Preconditioning Improves Outcome at 6 Years After Elective Percutaneous Coronary Intervention: The CRISP Stent Trial Long-term Follow-up. *Circ Cardiovasc Interv*. 2013;**6**:246-251.
85. Prasad A, Gossel M, Hoyt J, Lennon RJ, Polk L, Simari R, Holmes DR, Jr., Rihal CS, Lerman A. Remote ischemic preconditioning immediately before percutaneous coronary intervention does not impact myocardial necrosis, inflammatory response, and circulating endothelial progenitor cell counts: a single center randomized sham controlled trial. *Catheter Cardiovasc Interv*. 2013;**81**:930-936.
86. Basili S, Tanzilli G, Mangieri E, Raparelli V, Di SS, Pignatelli P, Violi F. Intravenous ascorbic acid infusion improves myocardial perfusion grade during elective percutaneous coronary intervention: relationship with oxidative stress markers. *JACC Cardiovasc Interv*. 2010;**3**:221-229.
87. Wang ZJ, Hu WK, Liu YY, Shi DM, Cheng WJ, Guo YH, Yang Q, Zhao YX, Zhou YJ. The effect of intravenous vitamin C infusion on periprocedural myocardial injury for patients undergoing elective percutaneous coronary intervention. *Can J Cardiol*. 2014;**30**:96-101.
88. Mangiacapra F, Peace AJ, Di SL, Pyxaras SA, Bartunek J, Wyffels E, Heyndrickx GR, Wijns W, De BB, Barbato E. Intracoronary Enalaprilat to Reduce MICROvascular Damage During Percutaneous Coronary Intervention (ProMicro) study. *J Am Coll Cardiol*. 2013;**61**:615-621.
89. Testa L, van Gaal WJ, Biondi Zoccai GG, Agostoni P, Latini RA, Bedogni F, Porto I, Banning AP. Myocardial infarction after percutaneous coronary intervention: a meta-analysis of troponin elevation applying the new universal definition. *QJM*. 2009;**102**:369-378.
90. Nienhuis MB, Ottervanger JP, Dambrink JH, de Boer MJ, Hoorntje JC, Gosselink AT, Suryapranata H, 't Hof AW. Comparative predictive value of infarct location, peak CK, and ejection fraction after primary PCI for ST elevation myocardial infarction. *Coron Artery Dis*. 2009;**20**:9-14.
91. Li Y, Pei H, Bulluck H, Zhou C, Hausenloy DJ. Periprocedural elevated myocardial biomarkers and clinical outcomes following elective percutaneous coronary intervention: a comprehensive dose-response meta-analysis of 44,972 patients from 24 prospective studies. *EuroIntervention*. 2020;**15**:1444-1450.
92. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Juni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO. 2018 ESC/EACTS Guidelines on myocardial revascularization. *Eur Heart J*. 2019;**40**:87-165.



93. Smith SC, Jr., Feldman TE, Hirshfeld JW, Jr., Jacobs AK, Kern MJ, King SB, III, Morrison DA, O'Neill WW, Schaff HV, Whitlow PL, Williams DO, Antman EM, Smith SC, Jr., Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention-Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). *J Am Coll Cardiol.* 2006;**47**:216-235.
94. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Juni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J.* 2018;**39**:213-260.
95. Silvain J, Lattuca B, Beygui F, Range G, Motovska Z, Dillinger JG, Boueri Z, Brunel P, Lhermusier T, Pouillot C, Larrieu-Ardilouze E, Boccara F, Labeque JN, Guedeney P, El KM, Laredo M, Dumaine R, Ducrocq G, Collet JP, Cayla G, Blanchart K, Kala P, Vicaut E, Montalescot G. Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial. *Lancet.* 2020;**396**:1737-1744.
96. Mehilli J, Baquet M, Hochholzer W, Mayer K, Tesche C, Aradi D, Xu Y, Thienel M, Gschwendtner S, Zadrozny M, Jochheim D, Sibbing D, Schupke S, Mansmann U, Hoffmann E, Kastrati A, Neumann FJ, Massberg S. Randomized Comparison of Intensified and Standard P2Y12-Receptor-Inhibition Before Elective Percutaneous Coronary Intervention: The SASSICAIA Trial. *Circ Cardiovasc Interv.* 2020;**13**:e008649.
97. Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, Pinto FJ, Ibrahim R, Gamra H, Kiwan GS, Berry C, Lopez-Sendon J, Ostadal P, Koenig W, Angoulvant D, Gregoire JC, Lavoie MA, Dube MP, Rhainds D, Provencher M, Blondeau L, Orfanos A, L'Allier PL, Guertin MC, Roubille F. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. *N Engl J Med.* 2019;**381**:2497-2505.
98. Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, The SHK, Xu XF, Ireland MA, Lenderink T, Latchem D, Hoogslag P, Jerzewski A, Nierop P, Whelan A, Hendriks R, Swart H, Schaap J, Kuijper AFM, van Hessen MWJ, Saklani P, Tan I, Thompson AG, Morton A, Judkins C, Bax WA, Dirksen M, Alings M, Hankey GJ, Budgeon CA, Tijssen JGP, Cornel JH, Thompson PL. Colchicine in Patients with Chronic Coronary Disease. *N Engl J Med.* 2020;**383**:1838-1847.
99. Shah B, Pillinger M, Zhong H, Cronstein B, Xia Y, Lorin JD, Smilowitz NR, Feit F, Ratnapala N, Keller NM, Katz SD. Effects of Acute Colchicine Administration Prior to Percutaneous Coronary Intervention: COLCHICINE-PCI Randomized Trial. *Circ Cardiovasc Interv.* 2020;**13**:e008717.
100. Miller WL, Garratt KN, Burritt MF, Reeder GS, Jaffe AS. Timing of peak troponin T and creatine kinase-MB elevations after percutaneous coronary intervention. *Chest.* 2004;**125**:275-280.

101. Cutlip DE. Procedural Myocardial Infarction: Definitions Everywhere, But Not Any That May Fit. *J Am Coll Cardiol.* 2020;**76**:1640-1643.
102. Huang C, Murugiah K, Mahajan S, Li SX, Dhruva SS, Haimovich JS, Wang Y, Schulz WL, Testani JM, Wilson FP, Mena CI, Masoudi FA, Rumsfeld JS, Spertus JA, Mortazavi BJ, Krumholz HM. Enhancing the prediction of acute kidney injury risk after percutaneous coronary intervention using machine learning techniques: A retrospective cohort study. *PLoS Med.* 2018;**15**:e1002703.
103. Mortazavi BJ, Bucholz EM, Desai NR, Huang C, Curtis JP, Masoudi FA, Shaw RE, Negahban SN, Krumholz HM. Comparison of Machine Learning Methods With National Cardiovascular Data Registry Models for Prediction of Risk of Bleeding After Percutaneous Coronary Intervention. *JAMA Netw Open.* 2019;**2**:e196835.
104. Gibson WJ, Nafee T, Travis R, Yee M, Kerneis M, Ohman M, Gibson CM. Machine learning versus traditional risk stratification methods in acute coronary syndrome: a pooled randomized clinical trial analysis. *J Thromb Thrombolysis.* 2020;**49**:1-9.
105. Zack CJ, Senecal C, Kinar Y, Metzger Y, Bar-Sinai Y, Widmer RJ, Lennon R, Singh M, Bell MR, Lerman A, Gulati R. Leveraging Machine Learning Techniques to Forecast Patient Prognosis After Percutaneous Coronary Intervention. *JACC Cardiovasc Interv.* 2019;**12**:1304-1311.

**Table 1**  
**Definitions of periprocedural myocardial injury and infarction in patients with normal baseline (pre-PCI) cTn values**

<b>Group</b>	<b>Periprocedural Myocardial Injury</b>	<b>Periprocedural Myocardial Infarction</b>
Joint ESC/ACC Myocardial Infarction Redefined Consensus Document First UDMI (2000) <sup>16</sup>	Not available	>1x 99 <sup>th</sup> percentile URL cTn increase
Second UDMI (2007) <sup>17</sup>	>1x 99 <sup>th</sup> percentile URL cTn increase	Type 4a MI  >3x 99 <sup>th</sup> percentile URL cTn increase
ARC-1 (2007) <sup>18</sup>	Not available	>3x URL cTn increase
Third UDMI (2012) <sup>19</sup>	>1x 99 <sup>th</sup> percentile URL cTn increase  >5x 99 <sup>th</sup> percentile URL cTn increase in the absence of ischaemic, angiographic or imaging findings.	Type 4a MI  >5x 99 <sup>th</sup> percentile URL cTn increase within 48 hours of procedure plus at least one of: 1. Evidence of prolonged ischaemia (≥20 min) as demonstrated by prolonged chest pain 2. Ischaemic ST changes or new pathological Q waves 3. Angiography evidence of a flow-limiting complication 4. Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality
SCAI (2014) <sup>20</sup>	Not available	≥70x ULN cTn increase in patients with normal baseline cTn  ≥35x ULN cTn increase plus new pathologic Q-waves in ≥2 contiguous leads (or new persistent LBBB).
ARC-2 (2018) <sup>6</sup>	≥70x URL cTn increase within 48 hours of procedure	≥35x URL cTn increase within 48 hours of procedure with one of below: 1. New significant Q waves or equivalent 2. Flow-limiting angiographic complications 3. New "substantial" loss of myocardium on imaging
Fourth UDMI (2018) <sup>7</sup>	>1x 99 <sup>th</sup> percentile URL increase cTn	Type 4a MI  >5x 99 <sup>th</sup> percentile URL cTn increase within 48 hours of procedure plus at least one of: 1. New ischaemic ECG changes. Development of new pathological Q waves 2. Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality in a pattern consistent with an ischaemic aetiology 3. Angiographic findings consistent with a periprocedural flow-limiting complication 4. Post-mortem demonstration of a procedure-related thrombus in the culprit artery, or a macroscopically large circumscribed area of necrosis with or without intra-myocardial haemorrhage.

**Table 2**

**Independent predictors of periprocedural myocardial injury, type 4a MI and MACE in patients undergoing PCI**

Independent predictors of periprocedural myocardial injury and type 4a MI	Independent predictors of MACE
<p><b>Patient factors</b>            Age<sup>3;62</sup>            Renal failure<sup>64;65</sup>            Elevated baseline of cTn<sup>64</sup>            Current congestive heart failure<sup>27</sup></p> <p><b>Lesion characteristics</b>            Multi-vessel<sup>66</sup>            Bifurcation lesion<sup>64</sup>            Left main disease<sup>3;62</sup></p> <p><b>Procedure factors</b>            Stent length<sup>3;62;64</sup>            Stent diameter<sup>62</sup>            Number of stents<sup>26;62</sup>            Multi-vessel PCI<sup>27;68</sup>            Rotational atherectomy<sup>27</sup>            Retrograde approach for CTO<sup>68</sup></p>	<p><b>Patient factors</b>            Advanced age (<math>\geq 75</math> years)<sup>3;23;24;26;27;62;63</sup>            Diabetes<sup>23;24;62</sup>            Renal failure<sup>3</sup>            Peripheral vascular disease<sup>24</sup>            Previous stroke<sup>27</sup>            Previous MI<sup>27</sup>            Ever smoked<sup>24</sup>            COPD<sup>24</sup>            Ejection fraction<sup>24;63</sup>            Current congestive heart failure<sup>26;27</sup>            Elevated baseline of cTn<sup>28;34;35;67</sup></p> <p><b>Lesion characteristics</b>            Left mainstem<sup>3</sup>            Calcified<sup>24;25</sup>            SVG<sup>24</sup></p> <p><b>Procedure factors</b>            Multi-vessel stenting<sup>3</sup>            Stent length <math>&gt;30\text{mm}</math><sup>3</sup>            Post-procedural bleeding<sup>27</sup></p>


cTn – cardiac troponin, PCI – percutaneous coronary intervention, CTO – chronic total occlusion, MI – myocardial infarction, COPD – chronic obstructive pulmonary disease, SVG – saphenous vein graft.

**Table 3. Therapeutic strategies for preventing periprocedural myocardial injury and type 4a MI in CCS patients undergoing PCI**

<b>Agent</b>	<b>Timing of administration</b>	<b>Potential mechanism of action</b>	<b>Main study findings</b>	<b>Strength of evidence</b>
<i>High-dose Statins</i>	Pre-PCI	Pleiotropic effect on inflammation <sup>69,70</sup> Production of endothelial progenitor cells <sup>70</sup>	↓ Incidence of periprocedural myocardial injury and type 4a MI <sup>71-74</sup>  ↓ Incidence of MACE (death, reinfarction and revascularisation) <sup>75</sup>	Multiple randomised controlled trials <sup>71-74</sup>  However, neutral effect in some studies <sup>76-78</sup>
<i>Cangrelor</i>	At the time of PCI (intravenous)	Antiplatelet drug	↓ Incidence of periprocedural myocardial injury and type 4a MI <sup>79</sup>	One large randomised controlled trial <sup>79</sup>
<i>Remote ischaemic conditioning</i>	Pre-PCI	Reduces acute myocardial ischaemia-reperfusion injury	↓ Incidence of periprocedural myocardial injury and type 4a MI <sup>80-83</sup>  ↓ Incidence of MACE (but not powered for clinical outcomes) <sup>84</sup>	Multiple randomised controlled trials <sup>80-83</sup>  However, neutral effect in one study <sup>85</sup>
<i>Vitamin C</i>	Pre-PCI	Antioxidant effects	↑ Microcirculatory reperfusion ↓ Incidence of periprocedural myocardial injury <sup>86,87</sup>	Single randomised controlled trial of 532 patients <sup>87</sup>
<i>Enalaprilat</i>	At the time of PCI (intracoronary)	Endothelium-dependent epicardial coronary vasodilation mediated by endogenous bradykinin activity	↓ Incidence of periprocedural myocardial injury <sup>88</sup>	Single small randomised controlled trial of 40 patients <sup>88</sup>

PCI: percutaneous coronary intervention; MACE: major adverse cardiovascular events

**Figure 1: Potential causes of periprocedural myocardial injury and type 4a MI in CCS patients undergoing PCI**




**Figure 2: Summary of periprocedural myocardial injury and Type 4a MI in CCS patients undergoing PCI**

This figure provides an overview of the definitions, incidences, and potential impact on clinical outcomes of periprocedural myocardial injury and type 4a MI as defined by the Fourth UDMI in CCS patients undergoing PCI. In this Consensus Document, we introduce a new category of major periprocedural myocardial injury, which has been shown to be prognostically relevant in CCS patients undergoing PCI.

\*Some of these studies included both ACS and CCS patients.

AdjOR – adjusted Odds Ratio; CCS - chronic coronary syndrome; MACE – major adverse cardiac events; MI – myocardial infarction; OR – Odds ratio; HR – Hazards Ratio; PCI - percutaneous coronary intervention; UDMI – Universal Definition of Myocardial Infarction; URL – upper reference limit.




**Figure 3: Diagnostic algorithm for periprocedural myocardial injury and type 4a MI in CCS patients undergoing PCI**

In this Consensus Document, we propose a diagnostic algorithm for periprocedural myocardial injury and type 4a MI in CCS patients undergoing PCI, which is based on post-PCI elevation of cTn values, and the presence of ECG/imaging/angiographic evidence of new myocardial ischaemia as stipulated in the Fourth UDMI.

Patients with suspected major periprocedural myocardial injury, based on post-PCI cTn elevation of >5x 99<sup>th</sup> percentile URL, the ECG and coronary angiogram should be carefully reviewed, and cardiac imaging (e.g. echocardiography) performed to actively exclude the diagnosis of type 4a MI. The presence of either major periprocedural myocardial injury or type 4a MI in CCS patients undergoing PCI is prognostically relevant, as both have been shown to be independent predictors of mortality at one-year post PCI. In patients with elevated baseline (pre-PCI) cTn in whom the cTn values are stable ( $\leq 20\%$  variation) or falling, the post-PCI cTn values must rise by >20%. However, the absolute post-PCI value must still be >5x 99<sup>th</sup> percentile URL to diagnose major periprocedural myocardial injury or type 4a MI.

CCS - chronic coronary syndrome; PCI - percutaneous coronary intervention; URL – upper reference limit.





## Graphical Abstract

This figure provides an overview of the suggested approach to diagnosing the presence of 'minor' and prognostically relevant 'major' periprocedural myocardial injury (as defined in this Consensus document) and type 4a MI (as defined by the Fourth UDMI) in CCS patients undergoing PCI.

CCS - chronic coronary syndrome; MI – myocardial infarction; PCI - percutaneous coronary intervention

